NCT03304093 - Immunotherapy by Nivolumab for HIV+ Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2022

Conditions

Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer Stage IIIBHIV/AIDS

Interventions

DRUG

Nivolumab Injection

Nivolumab 3mg/kg every 2 weeks

Trial Locations (18)

Saint Brieuc - CHG, Saint-Brieuc

Montpellier - CHRU, Montpellier

NHC - Pneumologie, Strasbourg

Centre Hospitalier - Pneumologie, Le Mans

APHP - Hopital Tenon - Pneumologie, Paris

Suresnes - Hopital Foch, Suresnes

CH d'Avignon, Avignon

CH de la Côte Basque, Bayonne

CH Cahors, Cahors

CH, Colmar

CHI Créteil, Créteil

Hôpital de la Croix Rousse, Lyon

AP-HM Hôpital Nord, Marseille

Montpellier - ICM, Montpellier

Paris - APHP Bichat, Paris

Paris - Pitié-salpêtrière, Paris

CH de Pau, Pau

CHU Toulouse - Pneumologie, Toulouse

All Listed Sponsors

collaborator

ANRS, Emerging Infectious Diseases

OTHER_GOV

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER